Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
相关临床试验
11
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
9.1%
已完成
7
63.6%
招募中
1
9.1%
撤回
2
18.2%
暂无批准数据
- DelveInsight's 2025 analysis reveals over 30 companies are actively developing more than 30 therapeutic candidates for liver cirrhosis, driven by rising global prevalence of liver diseases, particularly NAFLD associated with obesity and metabolic syndrome. - Sagimet Biosciences received FDA Breakthrough Therapy and Fast Track designations for denifanstat in February 2025, while Madrigal Pharmaceuticals plans to launch REZDIFFRA in Europe starting with Germany in the second half of 2025. - Multiple Phase III trials are progressing, including Akero Therapeutics' completed enrollment in the SYNCHRONY Real-World study with results expected in the first half of 2026, and ongoing ENLIGHTEN trials for MASH cirrhosis. - Key investigational therapies advancing through clinical development include Volixibat, TVB-2640, belapectin, RTX001, and LPCN 1148, representing diverse mechanisms of action from sodium-bile acid cotransporter inhibition to macrophage cell therapy.
- Denifanstat demonstrated an 85% response rate for fibrosis regression in advanced qF4 MASH patients compared to 33% with placebo in a secondary analysis of the FASCINATE-2 trial. - In F3 MASH patients, denifanstat achieved a 34% response rate for ≥2-stage fibrosis improvement without MASH worsening versus 4% with placebo (p=0.0065). - AI-based digital pathology and spatial computational histology revealed that denifanstat significantly improved multiple noninvasive biomarkers including FibroScan (-29% vs +26% placebo) and liver fat content (-34% vs +14% placebo). - The findings support denifanstat's potential as a breakthrough therapy for non-cirrhotic MASH, a progressive liver disease affecting over 265 million people worldwide with limited treatment options.
- Denifanstat (ASC40), a first-in-class oral fatty acid synthase inhibitor, achieved statistically significant improvements in all primary and secondary endpoints in a Phase III trial for moderate to severe acne vulgaris. - The drug demonstrated 33.2% treatment success versus 14.6% for placebo and showed superior efficacy compared to FDA-approved treatments, being 98% more effective than sarecycline and 178% more effective than doxycycline. - Denifanstat exhibited a favorable safety profile with no serious adverse events and addresses acne's underlying cause by directly inhibiting sebum production through a novel mechanism of action. - Ascletis plans to submit the treatment to China's National Medical Products Administration soon, potentially offering a breakthrough oral therapy for acne patients.
- DelveInsight's 2025 pipeline analysis reveals over 30 companies developing 30+ liver cirrhosis therapies, with promising candidates like Rezdiffra, efruxifermin, and belapectin showing significant clinical progress. - Madrigal Pharmaceuticals' Rezdiffra demonstrated reduced liver scarring in compensated cirrhosis patients in Phase 3 MAESTRO-NAFLD-1 trial data, while Akero Therapeutics reported preliminary results from its Phase IIb SYMMETRY study of efruxifermin. - The liver cirrhosis treatment market is experiencing robust growth driven by rising global prevalence of liver diseases, particularly NAFLD, fueled by lifestyle factors including obesity and metabolic syndrome. - Key pipeline therapies span diverse mechanisms including sodium-bile acid cotransporter inhibitors, regulatory T-lymphocyte stimulants, and Wnt signaling pathway inhibitors across oral, intravenous, and subcutaneous administration routes.
• ProQR Therapeutics has appointed Dennis Hom as CFO and Dr. Cristina Lopez Lopez as CMO to support the advancement of its Axiomer™ RNA editing technology platform into clinical development. • Dennis Hom brings over 25 years of financial leadership experience, having raised more than $4.5 billion in capital and executed transactions exceeding $57 billion in value throughout his career. • Dr. Cristina Lopez Lopez contributes 20+ years of global R&D leadership with expertise in translational science, previously serving as Global Head of Neurodegeneration at Johnson & Johnson.
• Sagimet Biosciences has received FDA clearance for its Investigational New Drug application for TVB-3567, a selective fatty acid synthase inhibitor targeting acne treatment. • The company plans to initiate a first-in-human Phase 1 clinical trial in 2025, expanding its therapeutic portfolio into dermatology while building on positive data from its first FASN inhibitor. • TVB-3567 targets sebum production, a primary contributor to acne pathogenesis, potentially offering a differentiated treatment option for the 50+ million Americans affected by this common skin condition.
• Sagimet Biosciences will present on fatty acid synthase (FASN) inhibitors at the 9th Annual MASH-TAG Conference on January 10, 2025. • The presentation will highlight denifanstat's differentiated mechanism of action and anti-fibrotic effects observed in the Phase 2b FASCINATE-2 study. • Denifanstat, an oral, once-daily FASN inhibitor, is being developed for metabolic dysfunction-associated steatohepatitis (MASH) treatment. • The FDA granted Breakthrough Therapy designation to denifanstat for non-cirrhotic MASH with moderate to advanced liver fibrosis.
• Sagimet Biosciences' Denifanstat receives FDA Breakthrough Therapy designation for metabolic dysfunction-associated steatohepatitis (MASH), accelerating its development and review process. • Phase 2b FASCINATE-2 trial demonstrates statistically significant improvements in liver health metrics, resolving MASH and improving fibrosis, key indicators for the condition. • Denifanstat, an oral FASN inhibitor, shows a direct anti-fibrotic effect not observed in other NASH drugs, with potential efficacy across multiple indications. • Analyst coverage highlights strong growth potential for Sagimet, with Oppenheimer initiating coverage with an Outperform rating and a price target of USD$30.00.
• Sagimet Biosciences is set to initiate two Phase 3 trials, FASCINATE-3 and FASCINIT, by the end of 2024 for non-cirrhotic MASH treatment. • Denifanstat, Sagimet's drug, received breakthrough therapy designation, indicating strong regulatory support and promising clinical trial outcomes. • With $170 million in cash, Sagimet's financial stability supports operations through 2025, enhancing its growth potential. • Analyst Ritu Baral from TD Cowen and UBS initiated coverage with a Buy rating on Sagimet's stock, citing strategic advancements.
• Sagimet Biosciences' denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). • Phase 2b FASCINATE-2 study results, published in The Lancet Gastroenterology & Hepatology, demonstrated significant improvements in disease activity, MASH resolution, and fibrosis with denifanstat. • Sagimet has completed end-of-Phase 2 interactions with the FDA and plans to initiate a Phase 3 program for denifanstat by the end of 2024. • The company's cash runway extends through 2025, with $170.0 million in cash, cash equivalents, and marketable securities as of September 30, 2024.
